Never claimed to have made medicine for COVID-19: Patanjali Ayurved
Patanjali has never claimed to make corona medicine. Rather, corona patients have been cured with this medicine. The drug was made under the license issued by the Ayush Ministry, Patanjali Ayurved CEO Acharya Balakrishna said
Patanjali Ayurved on Tuesday said that it never claimed to have made a medicine for coronavirus. The Haridwar-based organisation has withdrawn from its earlier claim, in reply to the notice given by Uttarakhand Ayush Ministry.
We never told the medicine (coronil) can cure or control corona, we said that we had made medicines and used them in clinical controlled trial which cured corona patients. There is no confusion in it: Acharya Balkrishna, CEO Patanjali pic.twitter.com/LfPCxML0jg— ANI (@ANI) June 30, 2020
"Patanjali has never claimed to make corona medicine. Rather, corona patients have been cured with this medicine. The drug was made under the license issued by the Ayush Ministry," stated the reply by Patanjali Ayurved CEO Acharya Balakrishna to the notice.
"We made the combination of Tulsi Giloy Ashwagandha at an advanced level and when the clinical trials were done on the patients of COVID-19, the coronavirus patients were cured. A conspiracy has been hatched against us and if the Ayush Ministry tells us to conduct clinical trials once again then we are ready to face it," he added.
Earlier in the month, Patanjali Ayurved, in collaboration with NIMS University, launched Coronil and Shwasari Vati, claiming to cure corona patients.
Mid-Day is now on Telegram. Click here to join our channel (@middayinfomedialtd) and stay updated with the latest news
This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever
Sign up for all the latest news, top galleries and trending videos from Mid-day.comSubscribe